TNRMCi001-A

iTAF32

General

Cell Line

hPSCreg name TNRMCi001-A
Cite as:
TNRMCi001-A (RRID:CVCL_D0MZ)
Alternative name(s)
iTAF32
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
RCMGi013-A
(P2L2)
Donor's gene variants:
CFTR
Donor diseases:
Cystic Fibrosis
RCMGi001-A
(P1L5)
Donor diseases:
Cystic Fibrosis
RCMGi004-B
(P6L8)
Donor diseases:
Cystic Fibrosis
RCMGi004-A
(P6L2)
Donor diseases:
Cystic Fibrosis
MUBi002-A
(CF 001)
Donor diseases:
Cystic fibrosis
RCMGi005-A
(P5L1)
Donor diseases:
Cystic Fibrosis
RCMGi005-B
(P5L5)
Donor diseases:
Cystic Fibrosis
KCLe003-A
(KCL-003-CF-1)
Donor diseases:
Cystic fibrosis
ULBe004-A
(ERAMUC-1)
Donor diseases:
Cystic Fibrosis
RCMGi008-A
(P9L1)
Donor diseases:
Cystic Fibrosis
MHHi002-A
(CF(1)iPS5)
Donor diseases:
Cystic fibrosis
IGGi002-A
Donor diseases:
Cystic Fibrosis
RGIe156-A
(SI-257)
Donor diseases:
Cystic fibrosis
MHHi003-A
(CF(15)iPS10)
Donor diseases:
Cystic fibrosis
MHHi004-A
(CF(16)iPS1)
Donor diseases:
Cystic fibrosis
RCMGi007-A
(P8L2)
Donor diseases:
Cystic Fibrosis
MHHi005-A
(CF(17)iPS6)
Donor diseases:
Cystic fibrosis
RCMGi002-A
(P7L2)
Donor diseases:
Cystic Fibrosis
INSRMe008-A
(STR-I-203-CFTR)
Donor diseases:
Cystic fibrosis
INSRMe009-A
(STR-I-251-CFTR)
Donor diseases:
Cystic fibrosis
VUBe004-A
(VUB04_CF)
Donor diseases:
Cystic fibrosis
HADe002-A
(HAD 2)
Donor diseases:
Cystic fibrosis
ZZUi030-A
(ZZU-iPS-SPG7-001)
Donor diseases:
Spastic paraplegia type 7
DHMi004-A
(HOS_1460)
Donor diseases:
Holt-Oram Syndrome
UNIZARi001-A
(FiPSTK2-2)
Donor's gene variants:
TK2, TK2
Donor diseases:
Mitochondrial DNA depletion syndrome, myopathic form
UTSWi001-A
(FA1)
Donor diseases:
Friedreich Ataxia
UPITTi004-A
(CN090 C5A5J2)
Donor diseases:
Sickle cell anemia
UPITTi004-B
(CN090 C1B5B5)
Donor diseases:
Sickle cell anemia
BGUi001-A
(BGU01iPORhet)
Donor diseases:
P450 Oxidoreductase Deficiency
BGUi002-A
(BGU02iPOR)
Donor diseases:
P450 Oxidoreductase Deficiency
BGUi003-A
(BGU03iPOR)
Donor diseases:
P450 Oxidoreductase Deficiency
VUi011-A
(SCZ 3.5)
Donor diseases:
Schizophrenia
LUMCi002-A
(113-6, LUMC0113iATAX06)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-B
(113-7, LUMC0113iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-C
(113-8, LUMC0113iATAX08)
Donor diseases:
Spinocerebellar Ataxia Type 1
HDZi003-A
(hiPSC NP0038)
Donor's gene variants:
TMEM43
Donor diseases:
arrhythmogenic right ventricular dysplasia 5
FRIMOi004-A
(STGD2_ FiPS4F1.7)
Donor diseases:
Stargardt Disease
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
Last update 22nd August 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Tomsk National Research Medical Center of the Russian Academy of Sciences (TNRMC)
Owner Tomsk National Research Medical Center of the Russian Academy of Sciences (TNRMC)
Distributors
Derivation country Russia

External Databases

BioSamples SAMEA114292483
Cellosaurus CVCL_D0MZ
Wikidata Q123033635

General Information

* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 15-19
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Mucoviscidosis
  • CF
Genetic variants
CFTR (target)
Chr7: 117559591 - 117559593 (on Assembly GRCh38)
NM_000492.3(CFTR):c.1521_1523del (p.Phe508del)
Disease associated phenotypes no phenotypes

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA114292484

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. Nikolay A. Skryabin, PhD, nukulay@gmail.com
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? No
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? No
a non-profit company? No
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Nikolay A. Skryabin, PhD, nukulay@gmail.com
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website: Nikolay A. Skryabin, PhD, nukulay@gmail.com
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Research Ethics Committee of the Research Institute of Medical Genetics of the Tomsk National Research Medical Center (Tomsk, Russia)
Approval number
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Research Ethics Committee of the Research Institute of Medical Genetics of the Tomsk National Research Medical Center (Tomsk, Russia)
Approval number Protocol number 10 (15.02.2021)
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Epi5™ Episomal iPSC Reprogramming Kit, Invitrogen™???
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms
Source cell origin
Age of donor (at collection) 15-19
Collected in 2022
Passage number reprogrammed 1

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced
Vector map

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Colonies of iPSCs were selected with the most pronounced iPSC-like morphology, optimal size, and a neat smooth edge.
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells Mouse embryonic fibroblast
Passage method Enzymatically
TrypLE
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F-12, GlutaMAX Supple
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEAA 0.1 mM
GlutaMAX-I Supplement 2 mM
β-mercaptoethanol 0.1 mM
rhFGF basic 10 ng/ml
Penicillin-Streptomycin 100 U/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
NANOG
Yes
SSEA-4
Yes
SOX2
Yes
TRA 1-60
Yes
Score:
Marker Present Absent
mCpG
OCT4
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
AFP
Yes
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Collagen I
Yes
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
NEFH
Yes
Morphology

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 17
Karyotyping method: G-Banding

Other Genotyping (Cell Line)